480 Results (Page 11 of 20)
Germany Markets Research Reports
Germany ENT Devices Market Analysis
Germany's ENT Devices Market is projected to grow from $850 Mn in 2022 to $1160 Mn by 2030, registering a CAGR of 4% during the forecast period of 2022-30. The rising prevalence of ENT disorders, such as hearing loss, sinusitis, and tonsillitis, is a major driver of the ENT device market. The market is highly competitive, with a large number of players operating in the space, ranging from small, specialized companies to large multinational corporations. The domestic key players in the German ENT devices market include Spiggle & Theis, VBM Medizintechnik, and Heinz Kurz.
Germany Diabetes Therapeutics Market Analysis
German diabetes therapeutics market is expected to grow from $5.26 Bn in 2022 to $9.67 Bn in 2030 with a CAGR of 7.9% for the forecasted year 2022-30. The growing prevalence of diabetes and various other factors like obesity and lack of exercise are contributing to the expansion of the market. The German diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel. Esteve Pharmaceuticals, Celares, and Salix Pharmaceuticals are the major players in the German diabetes therapeutics market.
Germany Coronary Stents Market Analysis
Germany's Coronary Stents Market is expected to witness growth from $414 Mn in 2022 to $522 Mn in 2030 with a CAGR of 2.95% for the forecasted year 2022-30. In Germany, a rising older demographic and an increase in risk factors like obesity and diabetes are projected to contribute to the prevalence of coronary artery disease in Germany. Coronary stent demand as a treatment option is projected to increase as a result. The market is segmented by type, by mode of delivery, by materials and by end user. Some key players in this market include B. Braun, Biotronik, Medtronic, GE Healthcare, Boston Scientific and Philips Healthcare.
Germany Contraceptive Devices Market Analysis
Germany's Contraceptive Devices Market is expected to witness growth from $472 Mn in 2022 to $764 Mn in 2030 with a CAGR of 6.20% for the forecasted year 2022-30. The German populace is becoming more educated and aware of issues related to sexual health and contraception. The government and NGOs have taken steps to educate young people about the value of contraception, which has resulted in a rise in the use of contraceptive methods. The market is segmented by type and by gender. Some key players in this market include Riemser Arzneimittel, Femcare Medizintechnik, Bayer, Mylan Laboratories, Church & Dwight, CooperSurgical, Pfizer, Pregna International, and Teva Pharmaceutical.
Germany Cancer Immunotherapy Market Analysis
Germany's cancer immunotherapy market is expected to witness growth from $4.1 Bn in 2022 to $6.2 Bn in 2030 with a CAGR of 5.3% for the forecasted year 2022-30. The growing success rates of immunotherapy treatments and partnerships and collaborations between organizations to support the use of cancer immunotherapies in Germany are responsible for the growth of the market. The German cancer immunotherapy market is segmented by type, application, and end user. Immatics, Medigene, and Bayer are the major players in the German cancer immunotherapy market.
Germany Biosimilars Market Analysis
Germany's biosimilar market size was valued at $0.7 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 20.4% from 2022 to 2030 and will reach $3.1 Bn in 2030. The market is segmented by product type and indication type. The German biosimilar market will grow with the rising prevalence of chronic diseases in Germany, including cancer, diabetes, and autoimmune disorders. The key market players are Sandoz GmbH (AUT), Fresenius Kabi Deutschland GmbH (DEU), Hexal AG (DEU), STADA Arzneimittel AG (DEU), Sanofi-Aventis Deutschland GmbH (FRA), Teva GmbH (ISR), and others.
Germany 3D Imaging Market Analysis
Germany's 3D imaging market is projected to grow from $1.11 Bn in 2022 to $3.33 Bn by 2030, registering a CAGR of 14.7% during the forecast period of 2022-30. The market will be driven by technological advancements, an increase in the frequency of chronic diseases & rising demand for less invasive treatments. The market is segmented by product, application, by end-user & by portability. Some of the major players include Siemens Healthineers, Philips Healthcare & Carl Zeiss Meditec.
Germany Over The Counter (OTC) Pharmaceuticals Market Analysis
Germany's over-the-counter (OTC) pharmaceuticals market size was valued at $5032.5 Mn in 2022 and is estimated to expand at a CAGR of 3.74% from 2022 to 2030 and will reach $6750.8 Mn in 2030. OTC are non-prescription medications and are a vital component of the healthcare system, offering consumers accessible solutions for a wide range of common health issues. The market is segmented by product type and distribution channel. The key market players are Johnson and Johnson Services Inc (USA), Bayer AG (Germany), Novartis AG (Switzerland) and others.
Germany Alzheimer’s Disease Drugs Market Analysis
Germany's Alzheimer’s Disease Drugs market was valued at $564 Mn in 2022 and is estimated to expand at a CAGR of 6.62% from 2022-30 and will reach $942 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer drugs, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are AbbVie, AstraZeneca, Boehringer Ingelheim, Eisai Co., Eli Lilly and Company, Johnson and Johnson, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, Pfizer among others.
Germany Anemia Drugs Market Analysis
Germany's Anemia drugs market was valued at $585 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.1% from 2022-30 and will reach $1012 Mn in 2030. One of the main reasons propelling the growth of this market is an increase in chronic illness and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are 1A Pharma, 3B Pharmaceuticals, Abbott, AbbVie Germany, Abnova, AbZ-Pharma, Accord Healthcare, Amgen, and Pfizer among others.
Germany Healthcare Financial Analytics Market Analysis
The German Healthcare Financial Analytics market size was valued at $xx Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5% from 2022 to 2030 and will reach $xx Mn in 2030. The market is segmented by type, component, and deployment. Germany’s Healthcare Financial Analytics market will grow as the demand for data-driven decision-making is rising, and financial analytics. The key market players are IBM Watson Health, SAP Health, PwC Health, Deloitte Health, McKinsey Health, and others.
Germany Radiotherapy Market Analysis
By 2030, it is anticipated that the German radiotherapy Market will reach a value of $11.1 Bn from $6.6 Bn in 2022, growing at a CAGR of 6.6% during 2022-30. The Radiotherapy Therapeutics Market in Germany is dominated by a few domestic players such as Brainlab, Eckert & Ziegler, and Ziehm Imaging. The radiotherapy market in Germany is segmented into different types, technologies, procedures, applications, and end-users. The major risk factors associated with awareness of radiotherapy shortage of skilled staff, government initiatives, and reimbursement policy. The demand for German radiotherapy is increasing on account of the rise in cancer cases in the country.
Germany Multiple Myeloma Therapeutics Market Analysis
Germany's Multiple Myeloma Therapeutics Market was valued at $305 Mn in 2022 and is estimated to expand at a CAGR of 2.7% from 2022-30 and will reach $378 Mn in 2030. One of the main reasons propelling the growth of this Market is an increase in chronic disease, Increasing adoption of combination therapies. The Market is segmented by type, drug and distribution channel. Some key players in this Market are Abbott, MorphoSys, Merck, Medigene, Affimed, Helios Hospital, Vivantes Hospital Group and others.
Germany Patient Support Programs (PSP) Market Analysis
Germany Patient Support Programs (PSP) market is expected to grow from $xx Bn in 2022 to $xx Bn in 2030 with a CAGR of 8.1% for the year 2022-2030. The major factor responsible for the Germany Patient Support Programs (PSP) market is the increasing demand for patient-centric care for managing diseases in Germany. The market is segmented by functionality outlook, therapeutic outlook, application outlook, and end user. Some of the major PSP operators in the Germany Patient Support Programs (PSP) market are Ashfield Engage, CEBIS International, and Vitartis Medical Service.
Germany Telemedicine Market Analysis
This report presents a strategic analysis of the Germany Telemedicine Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Germany Telemedicine Market, offering unmatched value, accuracy and expert insights.
Germany Anti Aging Therapeutics Market Analysis
Germany's anti-ageing therapeutics market is projected to grow from $22 Mn in 2022 to $66 Mn in 2030 with a CAGR of 14.73% for the year 2022-30. The major factors responsible for the expansion of the market are the increased demand for anti-ageing treatment options as a result of the rising elderly population. The German anti-ageing therapeutics market is segmented by product, treatment, target group, type of ageing, type of molecules, mechanism of action, ingredient, and by distribution channel. Some of the leading players in the market include CureVac, Rentschler Biopharma, and Advancells.
Germany Acromegaly Therapeutics Market Analysis
Germany Acromegaly Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The prevalence and incidence of acromegaly and pituitary tumours are rising, as is global awareness of the disease. Technological advances in the development of new acromegaly medications are also key contributors to the market's growth. The high prevalence of hormonal problems, evolving lifestyles, and rising genetic disease incidence are all anticipated to fuel market expansion.Some of the key players in the global acromegaly therapeutics Market include Roche, Sanofi, GSK, Pfizer INC., Ipsen, Chiasma Inc, Validus pharmaceuticals LLC., Novartis AG, Amryt, Recordati, Sun Pharma, Crinetics Pharmaceuticals, Camurus, Ionis Pharmaceuticals , and Others.
Germany Adrenoleukodystrophy (ALD) Therapeutics Market Analysis
Germany Adrenoleukodystrophy (ALD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Drivers of acromegaly market are increasing cases of the disorder which in turn increased awareness and government focus motivated financial support to R&D. Poxel SA, Bluebird Bio Inc.,Viking Technologies, Minoryx Therapeutics sl., Apteeus SAS, Ashvattha Therapeutics LLC, NeuroVia Company, Autobahn Therapeutics Inc., Aldagen Inc., Celularity Inc., Imstem Biotechnology Inc., MedDay SA, and Orpheris Inc. are major competitors in the Germany Adrenoleukodystrophy (ALD) drugs market.
Germany Alport Syndrome Therapeutics Market Analysis
Germany during the forecast period of 2023-30, the Alport Syndrome therapeutics market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. Almost always affecting the kidney, Alport syndrome is a multisystem condition that also usually affects the inner ear and the eye. A variety of symptoms that normally start in childhood or adolescence and may get worse over time can be present. Invitae Corporation, Hoffmann-La Roche Ltd., Centogene N.V., and Eurofins Discovery are a few of the leading companies in the worldwide Alport syndrome market.
Germany Anal Fistula Therapeutics Market Analysis
Germany During the forecast period of 2023?2030, the Anal Fistula Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. A rare intestinal ailment that typically appears following an acute perianal abscess and is defined by improper connection between the lower rectum and the perianal skin. The market is expanding more quickly thanks to technological advancements in anal fistula therapy. The development of novel surgical treatment options and the explosive growth of the medical tourism business have contributed to the sector's segment expansion. The leading companies profiled in the market research study on anal fistula treatment include Becton, Medtronic, Dickinson and Company, Gem Srl, Biolitec AG, BD, Johnson & Johnson Services, Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, W. L. Gore & Associates, Cook, KARL STORZ SE & Co. KG, Novartis AG, Boehringer Ingelheim International GmbH, Pfizer.
Germany Angelman Syndrome Therapeutics Market Analysis
Germany During the forecast period of 2023?2030, The Angelman Syndrome Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. An uncommon inherited neuro-developmental condition called Angelman Syndrome is marked by a severe developmental delay, sleep issues, jerky movements, and a lot of laughter. As the illness is more common, there are more government measures to manage it. This has also helped with research and development for condition treatment. These factors collectively represent the Angelman Syndrome Therapeutics Market's driving forces. Boston Children's Hospital, the Angelman Syndrome Foundation, Rady Children's Hospital in San Diego, General Hospital Corporation, Cincinnati Children's Hospital Medical Center, and others are major competitors in the market for treating Angelman syndrome.
Germany Ankylosing Spondylitis Therapeutics Market Analysis
Germany Ankylosing Spondylitis Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Ankylosing spondylitis is a kind of arthritis that affects connective tissues. The sacroiliac joints, which connect the spine to the pelvis, become inflamed, but in extreme situations, the spine's bones might fuse together and become very inflexible. A rough estimate of 1.1 Mn Americans, or one out of every 200 adults, are impacted. Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB, and many other leading companies are active in the ankylosing spondylitis global market. To increase their market share, these businesses engage in strategic alliances and acquisitions in addition to concentrating on research and development to bring novel therapies to market.
Germany Uveitis Therapeutics Market Analysis
Germany Uveitis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Uveitis is an inflammation of the uvea, which is the middle layer of the tissue that surrounds the eye and is made up of the iris, ciliary body, and choroid. The most typical extra-articular Spondyloarthritis symptom is uveitis (SpA) Increased healthcare financing, together with the development of drugs with improved efficacy and fewer side effects, has benefited technological advancements in the field, which together are serving as a potential driver of the uveitis therapeutic market. Several well-known companies involved in the development and marketing of uveitis medicines include Novartis AG, Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Johnson & Johnson, AbbVie Inc., and Allergan (now a division of AbbVie).
Germany Anthrax Therapeutics Market Analysis
Germany Anthrax therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Bacillus anthracis is the bacteria that causes anthrax (B. anthracis). The market for anthrax therapeutics is fueled by factors such the increased prevalence of bacterial infections, rising research funding, the development of innovative medicines for treating anthrax, and pipeline goods, which increase demand and stimulate market expansion. The current rise in healthcare spending in both developed and developing nations is anticipated to give manufacturers a competitive edge in the development of novel and ground-breaking products. Global industries in the Anthrax therapeutics market are Aristo Pharmaceuticals Private Limited, Indoco Remedies Ltd., Lupin, Deinove, Bayer AG, Pfizer Inc., Emergent, Soligenix, Zydus Group, Sanofi, Alembic Pharmaceuticals, Emergent, Sanofi, Porton Biopharma, Lupin, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd and many more
Germany ATTR (Transthyretin Amyloidosis) Therapeutics Market Analysis
Germany ATTR (Transthyretin Amyloidosis) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. An rare and progressive condition known as ATTR (Transthyretin Amyloidosis) is characterised by the buildup of aberrant proteins in the body, including misTTR. The market for treatments for transthyretin amyloidosis is primarily driven by the expansion of the population and the availability of favourable reimbursement programmes. The market is predicted to increase as a result of strategic actions done by major players such raising knowledge of the target conditions like ATTR and the long-term advantages of treatments that are currently accessible. The market for treating transthyretin amyloidosis is currently constrained by a number of factors, including low awareness of the condition in developing nations, misdiagnosis of the condition, high costs of disease diagnosis and treatment, the lack of adequate clinical trials, and the absence of effective medications. Pfizer Inc., Johnson & Johnson Services, Inc., Ionis Pharmaceuticals, Alnylam Pharmaceuticals, BridgeBio Pharma, Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Astellas Pharma, Inc., Prothena, SOM Biotech, and numerous others are global competitors in the ATTR (Transthyretin Amyloidosis) market.